Elia Sechi, Giovanni A Deiana, Mariangela Puci, Pietro Zara, Enzo Ortu, Caterina Porcu, Nicola Carboni, Paola Chessa, Elisa Ruiu, Arianna Nieddu, Paolo Tacconi, Antonello Russo, Davide Manca, M Margherita Sechi, Melania Guida, Roberta Ricciardi, Tommaso Ercoli, Marcello M Mascia, Antonella Muroni, Paolo Profice, Valeria Saddi, Maurizio Melis, Eleonora Cocco, Gregorio Spagni, Raffaele Iorio, Valentina Damato, Michelangelo Maestri, Stefano Sotgiu, Giovanni Sotgiu, Paolo Solla
INTRODUCTION/AIMS: The global incidence and prevalence of myasthenia gravis (MG) range between 6-31/million and 10-37/100,000, respectively. Sardinia is a high-risk region for different immune-mediated disorders, but the epidemiology of MG remains unclear. We determined the epidemiology of MG with acetylcholine receptor (AChR)-immunoglobulin G (IgG) and muscle-specific tyrosine kinase (MuSK)-IgG in the district of Sassari (North-Western Sardinia; population, 325,288). METHODS: From the laboratory of the University Hospital of Sassari (reference for AChR/MuSK-IgG testing in Sardinia since 1998) and the main neurology units in Sardinia, we retrospectively identified MG patients with (1) AChR-IgG and/or MuSK-IgG positivity by radioimmunoprecipitation assay; and (2) residency in the district of Sassari...
March 8, 2024: Muscle & Nerve